Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the neurodegenerative disease.
With the new Series B extension funding, the Cambridge, Mass.-based company has now raised $128 million to develop its headset that uses gamma frequency light and sound stimulation to combat the cognitive decline that’s the hallmark of Alzheimer’s. Cognito is currently undertaking a large study of the treatment and CEO Brent Vaughan told STAT he expects the company to complete the trial and submit data to the Food and Drug Administration for review by the end of 2025.
While under treatment, patients use the device for one hour per day in their homes. The light and sound is supposed to stimulate brain activity that’s disrupted by neurodegenerative conditions, potentially helping to preserve brain structure.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect